Boston, Mass. – The field of next generation RNA therapeutics continues to progress towards clinical translation, with enormous investments and collaborations, such as Orbital Therapeutics’ recent $270 million Series A financing, and Circular Genomics’ $8.3 million Series A for their first-in-class circular RNA-based clinical assays.
The3rd Next Generation RNA Therapeutics Summit returns to cover the depth and breadth of the next of generation RNAs, including circular RNA, self-amplifying RNA (saRNA) and beyond from discovery to clinic and towards scalable manufacturing, unlocking the huge therapeutic and commercial potential of this emerging class of modalities.
Join 120+ expert leaders in Discovery, R&D, Engineering, Preclinical Translation and CMC from the key stakeholders pioneering advances in RNA technologies and continue to fast-track these next generation therapies into the clinic, and towards patients faster.
Why Attend?
Investigate the most recent advancements and technologies in Self-Amplifying RNA therapeutics, focusing on enhancing manufacturing and analysis capabilities to elevate patient treatment outcomes and produce successful RNA medicines with high quality, traceability, & reliability with case studies from Replicate Bioscience, Johnson & Johnson, and Strand Therapeutics.
Explore the latest research findings on circular RNA and pinpoint the primary hurdles including improving yield, purity, and scalability in the manufacturing and analytics of circular RNA to increase clinical success of circular RNAs towards patients with invaluable insights from industry leaders at Orbital Therapeutics, Sail Biomedicines, & NoctuRNA Therapeutics.
Engage in an in-depth discussion regarding the ongoing immunogenicity studies aimed at mitigating off-target effects and evaluating the safety and efficacy of your of circular RNA, transfer RNA and self-amplifying RNA therapeutics. Explore the different strategies to ensure the optimal performance and safety profile of cutting-edge RNA with insights from Pfizer & Sanofi.
Address the importance of collaboration and investment in advancing pharma and biotech innovations, and discuss the strategies for mitigating risks and maximizing returns on investment with investor insights from Rothwell Figg as well as John Hopkins University & Capstan Therapeutics.
Unlock the widespread potential of circular RNA, transfer RNA and self-amplifying RNA therapeutics with improved sequence design, target selection and in vivo delivery to treat previously “incurable” diseases with unmet needs with insights from Atomic AI & Sanofi.
For further details about the summit, including registration, please click here.
Summit at a glance
When: May, 7-9, 2024
Venue: Hilton Boston Back Bay – 40 Dalton Street, Boston Mass. 02115